NCT00707135View on ClinicalTrials.gov

Rapamycin in Advanced Cancers

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

September 30, 2008

Study Completion Date

December 31, 2008

Conditions
Advanced Cancer
Interventions
DRUG

Rapamycin

Rapamycin given once weekly in escalating doses. Higher dose levels will be split with the half the dose given on day 1 and half the dose on day 2 (24 hours later).

Trial Locations (1)

60637

University of Chicago, Chicago

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

lead

University of Chicago

OTHER

NCT00707135 - Rapamycin in Advanced Cancers | Biotech Hunter | Biotech Hunter